Aptamers are synthetic molecules structured as single-stranded DNA or RNA oligonucleotides that can be designed to mimic the functional properties of monoclonal antibodies. They bind to the target molecules (typically soluble or cell-bound proteins) with high affinity (with picomolar to low nanomolar range) and specificity, and therefore can be an alternative to therapeutic antibodies or peptide ligands. This paper reviews published data regarding pharmacokinetics, pharmacodynamics and safety of aptamers from preclinical and clinical studies. Aptamers have been developed for the treatment of a variety of diseases, including cancer, macular degeneration,g cardiovascular disease, diabetes and anaemia of chronic diseases. There are several preclinical studies with unmodified aptamers, but the vast majority of aptamer trials in humans have been conducted with modified aptamers, because unmodified aptamers demonstrate metabolic instability, as well as rapid renal filtration and elimination. Various strategies have been developed to improve the pharmacokinetic profile of aptamers. Aside from chemical modification of nucleotides in order to stabilize them against nuclease degradation, the main modification to extend the half-life is pegylation. Therefore, the process of pegylation as well as its benefits and possible shortcomings will briefly be discussed.
Introduction
Aptamers are synthetic molecules structured as single-stranded DNA or RNA oligonucleotides that mimic the functional properties of monoclonal antibodies. They bind to the target molecules (typically soluble or cell-bound proteins) with high affinity (Kd in picomolar to low nanomolar range [1] ) and specificity, and therefore can be an alternative to therapeutic antibodies or peptide ligands. Aptamers are good candidates for targeted therapy and imaging thanks to their intrinsically low degree of immunogenicity, relatively low molecular weights and ease of manufacturing. It is both simple and inexpensive to chemically synthesise and modify them. Aptamers have been developed against therapeutically relevant targets in a variety of diseases (tumours, macular degeneration, and cardiovascular problems).
In this review, we will provide a comprehensive overview of data published regarding safety, pharmacokinetics and pharmacodynamics in current preclinical and clinical studies of aptamers (Table 2) . Despite performing a thorough search of relevant medical databases in order to include all available primary literature to date and to screen the references cited therein, it is possible that some publications may have been overlooked. We apologise to the authors of these publications.
Preclinical and clinical studies with unmodified aptamers
Data on the biodistribution of unmodified therapeutic aptamers are limited, but it is possible to compare the biodistribution of unmodified aptamers with the biodistribution of antisense oligonucleotides. Unmodified antisense oligonucleotides distribute rapidly and broadly from the plasma compartment to the tissues, with the highest concentrations in the liver, kidney, lymph nodes, spleen, and bone marrow [2] . All unmodified oligonucleotides (including aptamers) have major pharmacokinetic problems including metabolic instability and rapid renal filtration without unspecific protein binding [2] . This is the reason why almost every aptamer currently being studied is modified. In the following section we have gathered available data about pharmacokinetics, pharmacodynamics and safety of unmodified aptamers.
The first aptamer to be discussed is the RNA aptamer against osteopontin (OPN-R3). Osteopontin is a protein involved in various physiologic processes within the human body, including bone remodelling, immune functions, chemotaxis, cell activation and apoptosis. It has been shown that in many cancers osteopontin is over-expressed [3] . Manipulation of plasma osteopontin level may be beneficial. An RNA aptamer against osteopontin (OPN-R3) was tested in mice, and it showed the following pharmacokinetic data: a surprisingly long t 1/2 of 7.76 h, t max 3 h, C max 13.2 mmol/L after a 200 μg dose [4] . Interestingly, the elimination t 1/2 OPN-R3 was 10 times longer after intravenous injection than the 0.7 h observed when it was injected subcutaneously into mammary fat. The authors attributed the shorter elimination time after subcutaneous injection to a slower absorption from the subcutaneous space resulting in low bioavailability at non-saturating concentrations. This may be true if there are nonlinear pharmacokinetics-e.g. they are target dependent [4] . The aptamer alone was not taken up by breast cancer cells, which means that it only binds to extracellular osteopontin. Hence, it exerts its effect by blockade of signalling rather than via intracellular mechanisms. The likely mechanism is that osteopontin blockade reduces not only metastatic activity but also reduces the production of proteins involved in cellular growth and proliferation. The modified variant 5′-OPN-R3 aptamer with Cy3 fluorophore enhanced the cellular uptake of the aptamer. The in vitro t 1/2 (stability) was significantly increased from the 4.5-4.8 h range to 6.2 h, by 2′-Omethylation of the aptamer. With this modification the aptamer's affinity to osteopontin was also higher [4] .
In contrast to OPN-R3, another unmodified aptamer showed pharmacokinetic values more in line with expectations. The aptamer TTA1, which binds Tenascin C, was investigated in mice with xeno-grafted human tumours. Tenascin-C is a hexameric protein found in the extracellular matrix and plays an important role in embryogenesis, tumorigenesis, and wound healing [5] . TTA1 was rapidly cleared, had a t 1/2 of less than 2 min and showed a rapid tumour penetration into human tumour xenografts. Tumour retention was durable; rapid tumour uptake and blood clearance yielded a tumour-to-blood ratio of 50:1 within 3 h. Human tenascin-C protein was required for the aptamer to be taken up [6] .
AS1411 is a nucleolin-targeted DNA aptamer, and is assumed to be the most advanced aptamer within the cancer setting [7] . Nucleolin is a nucleolar phosphoprotein and it is over-expressed on the surface of some cancer cells. Nucleolin seems to be involved in proliferation and the survival of cells and it has been suggested that it plays a role in transcription, packing and transport of ribosomal RNA, as well as replication and recombination of DNA [8] . Data about pharmacokinetics are available from studies in rats after a single intravenous bolus, multiple injections on subsequent days and a continuous infusion for 4 days. Maximum plasma levels were attained shortly after the bolus infusion; 4 h after termination of dosing (1, 10 and 25 mg/kg) plasma levels were still found to be above the limit of quantification and 68% of injected dose was recovered in urine within 5 h, which reflected the rapid initial elimination phase, whereas only 1% of the injected dose was detected in bile. AS1411 has a prolonged t 1/2 compared to unmodified phosphodiester oligonucleotides. The aptamer AS1411 delayed tumour growth in nude mice with small cell lung cancer cells [7] . Toxicology studies of limited duration of AS1411 were performed in rats (single bolus infusions) and in dogs (using a 96 h continuous intravenous infusion), and no significant toxicity was observed [7] .
In a clinical trial the disposition of AS1411 aptamer followed linear kinetics, the plasma concentration declined rapidly in a monophasic manner after the cessation of infusion. The estimated mean systemic clearance of 111 ml/h/kg was similar to the glomerular filtration rate of 107 ml/h/kg, suggesting that the major clearance route may be renal filtration [9] . The volume of distribution at steady state ranged from 38 to 2520 ml/kg and was highly inconsistent between patients (CV%, 94.2); this may indicate different distribution patterns in different patients, possibly due to target dependent elimination [10] . Exposure to AS1411 was similar between the patient with the partial response and the other patients, which indicates that the response observed in this patient was not a result of greater exposure to the study drug [9] . In patients with solid tumours, AS1411 showed antitumour activity in patients with metastatic renal cell carcinoma in a phase I clinical trial. Doses ranged from 1 to 40 mg/kg/day, given as continuous infusions over 4-7 days for up to 2 cycles [9] . Among 12 patients, one complete and one partial response were noted. AS1411 also stabilised the disease in seven patients for a duration of N2 months. Overall efficacy results in this trial were quite disappointing. However, toxicity was low and there was one major durable response. This patient showed an 84% decrease in the sum diameters of target tumour lesions. Thirty-four months after the end of treatment with the study drug there was still no evidence of disease progression and additional therapy was not required. Although AS1411 has a low level of activity in unselected patients, it may be better suited to targeted therapy in selected patients [9] .
Unmodified aptamers have been used as a drug delivery system for a variety of molecules. For example, a nanoparticulate-paclitaxel drug delivery system was conjugated with AS1411 to deliver paclitaxel more efficiently to a glioma [11] . The nanoparticles with or without the aptamer prolonged the half-life in rats (from 1.79 h (paclitaxel alone) 2.3 and 3-fold, respectively). The aptamer-nanoparticle-paclitaxel resulted in significantly higher paclitaxel concentrations in the tumour [11] , inhibited tumour growth in mice bearing the C6 glioma xenograft more efficiently than paclitaxel, and increased survival in rats, when compared with standard therapy (paclitaxel). This was likely due to its elevated cellular association and its uptake facilitated by the nucleolin-AS1411 interaction [11] .
Due to their large molecule size, aptamers typically do not pass the blood brain barrier, which protects the brain [12] . Previous studies demonstrated that the biodistribution of aptamers to the brain is low after intravenous infusion, probably due to the limited ability of aptamers to pass through the blood brain barrier [13] . However, Cheng et al. have developed RNA aptamers capable of penetrating the blood brain barrier through in vivo SELEX process [12] . They injected 40 different aptamers into mice and measured the concentration of aptamers in the brain. They have managed to isolate an aptamer with the ability to distribute into the brain tissue. The exact way in which these aptamers cross the blood brain barrier is still unknown [12] . A couple of aptamers were designed for the treatment of multiple sclerosis, for example a DNA aptamer that binds myelin and promotes remyelination in a mouse model of multiple sclerosis. This aptamer was a 3′-biotin aptamer conjugate and it was injected biweekly for 5 weeks into the Theiler's encephalomyelitis virus-infected mice, which show multiple sclerosis-like lesions. Mice treated with the aptamer showed significantly more remyelination of the spinal cords than controls (35% vs. 4% respectively) [14] .
In summary, these studies showed that aptamers almost always have to be modified in order to be used in practice. Therefore, the next section will focus on the most common modifications, and the pharmacokinetics, pharmacodynamics and safety of these modified aptamers.
Preclinical and clinical studies with modified aptamers
Fundamental characteristics for successful therapeutic use of aptamers are high affinity and specificity for their targets as well as sufficient stability against in vivo nuclease degradation. There are several strategies that can stabilize aptamers against 3′ and 5′ exonucleases as well as endonucleases, while their target affinity is maintained [15] . Aptamers are easily chemically modified and this modification can alter their pharmacokinetic properties.
Chemical modifications of aptamers

Locked nucleic acids
In order to improve TTA1's (mentioned above) target binding, in vivo stability and to achieve maximal thermal stem stabilisation, investigators synthesised 3 different derivates of TTA1 (unmodified, 2′-O-methylated and Locked Nucleic Acids (LNA)-modified TTA1) [15] .
Briefly, locked nucleic acid modification (Fig. 2) represents a methylene linkage between 2′-O and 4′-C of the sugar ring in the ribonucleotide. The locked nucleic acids-modified TTA1 derivative showed only a 25% longer in vivo t 1/2 (compared to the unmodified aptamer) in tumour-bearing mice, although it showed significant stem stabilisation and improved plasma stability with maintained binding affinity. Additionally, tumour uptake was higher and blood retention was longer compared to either unmodified or methylated aptamer. The clearance was slower and was dominated by urinary excretion for the locked nucleic acid-modified aptamer and the methylated aptamer [15] .
That was in contrast to unmodified TTA1 which showed rapid faecal clearance, likely due to the RNA being degraded and excreted through the intestine. Altered distribution of modified TTA1 probably reflects increased stability and enhanced accumulation in kidney and liver cells due to slower degradation. The authors concluded that it is possible to make locked nucleic acids modifications of aptamers in order to improve the in vivo stability and tumour uptake of aptamers, without compromising their binding properties [15] .
Thiolation
Thiolation can improve nuclease stability and thermostability [16] . A mouse study estimated the safety of different intravenous doses of a mono-thioated aptamer against E-selectin (ESTA) when applied intravenously. E-Selectin is expressed only on endothelial cells and acts as a cell adhesion molecule, which is rapidly induced by cytokines. [17] The aptamer inhibits the interaction between E-selectin and CD44 and thereby the adhesion of CD44+ breast cancer cells to inflamed endothelial cells [18] . Conjugation of thioaptamer against E-selectin with liposomes decreased the clearance, increased the area under the curve (AUC) and slightly extended the t 1/2 after intravenous injection (in the tail vein) in tumour bearing mice, when compared to pegylated liposomes [19] . I. This study also investigated if 3′-biotin conjugation could increase the t 1/2 and increase stability against blood nucleases. Mice and rabbits received 3′-biotinstreptavidin (SA) bioconjugates (Fig. 3) of the aptamers. The 3′-biotin protected aptamers from blood nuclease degradation in vitro, but in vivo clearance was the same. On the other hand, the 3′-biotinstreptavidin bioconjugates were resistant to blood nuclease in vitro and they had extended lifetime in vivo. The affinity for thrombin was retained for both [20] .
Pegylation
Almost every aptamer had some modification before the pegylation process, such as sugar modifications (2′-fluoro, 2′-amino, 2′-O-methyl), or locked nucleic acids modifications etc. These modifications increase nuclease resistance and make the aptamers more thermostable. On the other hand, the most frequently used method for prolonging t 1/2 is pegylation (Fig. 4) (Table 1 ). In the following section, we will focus on the pegylated aptamers and on comparing pegylation with other methods. With pegylation it is possible to minimise renal filtration by increasing molecular size. It is also possible to improve the pharmacokinetics.
Aptamers pegylated with 20 kDa PEG unit
One study investigated the bio-distribution of pegylated and unpegylated methylated ( Fig. 1-V ) aptamers in healthy and inflamed tissues (ARC83, ARC120, ARC159) [21] . The target of these aptamers is transforming growth factor β2 (TGFβ2). Transforming growth factor β2 (TGFβ2) is a cytokine; which helps to control proliferation and growth of cells. The tritiated 20 kDa PEG conjugate (ARC120) was prepared using 3 H-ARC83 as starting material. ARC120 merely adds 20 kDa PEG to the ARC83, so it is predicted to bind to TGFβ2 with similar activity. ARC159 is a fully chemically-modified version of ARC83 without binding affinity for TGFβ2, which served as a control for the purpose of PK comparison [21] . Biodistribution was measured with whole body autoradiography. The total level of radioactivity for the pegylated aptamer was significantly higher in both whole body tissues and inflamed tissues than for other aptamers. High levels of pegylated aptamer were also seen in the liver, lungs, bone marrow and spleen, i.e. tissues and organs which are generally well perfused. Pegylation of the aptamer prolonged its in vivo t 1/2, while distribution to the kidneys was reduced and the urinary elimination was retarded. In contrast, a fully 2′-O-Me aptamer (ARC83) composition showed comparatively rapid clearance and increased urinary elimination. Quantitative autoradiography was used to measure the concentration of radioactivity in whole body tissues and hind limbs. At a cellular level the concentration of radioactivity was estimated using microautoradiography. Cellular uptake of 3 H was seen in the kidneys and the liver. In the kidney, clear accumulation of 3 H was seen in the distal tubules in animals dosed with 3 H -ARC120, with concentrations gradually increasing in the proximal to distal direction. Accumulation was also seen in liver sinusoidal lining cells in the animals dosed with 3 H -ARC120 [21] . Consistent with the elimination of aptamers mainly via urine, the highest concentrations of radioactivity in whole body tissues were observed in the kidney and urinary bladder. The pegylation allowed aptamers to remain in the bloodstream for longer; this is expected to increase exposure time of ARC120 to tissues and thus to promote aptamer uptake and persistence in the animal. The fully 2′-O-Me-modified control aptamer ARC159 showed the lowest level of whole body radioactivity among the aptamers. The primary site of tissue distribution of ARC159 was the kidney, because ARC159 was rapidly cleared from plasma. This aptamer also showed the highest level of radioactivity inside the gastrointestinal tract. It has been speculated that the hydrophobic nature of ARC159 may favour its association with factors that promote gastrointestinal uptake or transport [21] . This study also proved that modifications such as pegylation protect aptamers from renal filtration in vivo, improve pharmacokinetic properties and promote persistence of aptamers in circulation [21] . There are pegylated aptamers that are currently being researched and that were developed in order to provide a potentially safer therapy for cardiovascular disorders, such as an aptamer against von Willebrand factor [22] . As well as other functions, von Willebrand factor (VWF) mediates platelet adhesion and aggregation particularly under high shear rates [23, 24] [25] . At sites of arterial stenosis shear stress is elevated, activating VWF and triggering VWF-platelet binding [26] . As VWF is a carrier protein and a chaperone for blood clotting factor VIII, VWF stabilises and prevents factor VIII from early inactivation [27] . Endothelial cells and platelets release VWF, and the activation is induced by a number of agents including thrombin [28] or histamine [29] . Inhibiting the function of VWF improves outcome for patients with thrombotic thrombocytopenic purpura [30] and could be of potential benefit for patients suffering stroke [31] myocardial infarction [24] , and possibly other diseases such as malaria [32] or sickle cell disease [33] .
The anti-VWF aptamer ARC1779 aptamer blocks the interaction between the glycoprotein Ib receptor on platelets and VWF through binding to the A1 domain of activated VWF [34] . In rats, the radio-labelled anti-VWF aptamer ARC1779 distributed from the blood most notably to the spleen, liver, lymph nodes, kidneys (and urine) and bone marrow [35] . The addition of the PEG moiety of ARC1779 slowed the rate of exit from the blood to the tissue and the rate of filtration by the kidney decreased. When a radio-labelled aptamer enters the tissues, it is slowly cleared and 2 weeks after dosing 50% of the material remains in the body [35, 36] . In clinical trials, ARC1779 distributed primarily into the plasma component of the central compartment, with a low degree of inter-individual variability, and exhibited an apparent t 1/2 of elimination in the order of 2 to 3 h. The clearance values ranged from approximately 10% to 21% of the glomerular filtration rate, so pegylation of the anti VWF aptamer has likely decreased its renal clearance. After slow intravenous bolus infusion of ARC1779, the fitted EC50 and EC90 values for inhibition of VWF activity were 0.2 μg/ml (17 nmol/l) and 2.0 μg/ ml (151 nmol/l), respectively. Across all doses and dosing regimens, the relationship of ARC1779 concentration with inhibition of VWF activity and platelet function was consistent [34, 36] . The initial proof of concept (mentioned above) for thrombotic thrombocytopenic purpura (TTP) came from a named patient programme: a patient suffering from refractory TTP received repeated infusions of ARC1779 for 3 weeks in addition to plasma exchange (the standard treatment) [37] . Treatment with the aptamer successfully decreased VWF activity by N96%, and with plasma exchange (standard treatment) concentrations of ARC1779 decreased by a mean of 47%. Therefore, additional mini-bolus infusions were always given after plasma exchange. This trial demonstrated that ARC1779 increases platelet counts in TTP when it is given in addition to plasma exchange. The inhibition of VWF via ARC1779 was investigated further in two small clinical trials in patients suffering from acute thrombotic thrombocytopenic purpura [37, 38] . Patients received a bolus-primed continuous infusion of ARC1779 intravenously, which rapidly established steady state concentrations. One hour after the start of the bolus infusion, mean VWF A1 availability decreased from 125% to 5%. ARC1779 plasma concentrations were reduced by N50% after each plasma exchange, the standard therapy of thrombotic thrombocytopenic purpura. This confirms that the volume of distribution of ARC1779 equals the plasma volume, because approximately half of the plasma is removed during plasma exchange. Every plasma exchange therapy was followed by a mini-bolus which restored drug levels. In this study, the elimination t 1/2 was around 4 h, roughly comparable to the previously reported t 1/2 of approximately 2-3 h in healthy volunteers [34] .
Simultaneous restoration of free VWF A1 domains followed the withdrawal of ARC1779 infusion. VWF activity returned to values N100% 24 h after discontinuation of ARC1779. One prospective clinical trial compared three different ways of administering the anti-von Willebrand factor (VWF) aptamer ARC1779 in congenital thrombotic thrombocytopenic purpura patients: subcutaneous injections, a lowdose infusion and a high-dose infusion. This small trial effectively showed that drug levels were too low to successfully suppress VWF after daily subcutaneous injection, likely due to the drug's short halflife; similarly a low-dose i.v. infusion had only minimal pharmacodynamic impact [39] .
Von Willebrand type 2B (VWD type 2B) is a rare disease which is generated by mutations of von Willebrand factor (VWF) and causes hyperactivity of VWF, rather than deficiency of VWF [40] . The molecular defects in VWF type 2B enhance the affinity of VWF to glycoprotein Ib and thus binding to platelets [40] . Normal platelets and the mutated VWF molecules bind spontaneously and the metalloprotease ADAMTS-13 digests the high-molecular weight (HMW) multimers. Thus, VWD type 2B patients become deficient in both large platelets and VWF multimers. As a result, the major clinical symptoms of VWD type 2B are menorrhagia, epistaxis, and bleeding after trauma, childbirth or surgery. Desmopressin worsens thrombocytopenia in VWD type 2B by release of large and hyper-adhesive VWF multimers which agglutinate platelets. One pilot trial examined whether ARC1779 could possibly prevent thrombocytopenia induced by desmopressin as well as the extreme VWF turnover in VWF type 2B patients by blocking the binding of hyperfunctional VWF to glycoprotein Ib. Two patients with VWD type 2B received a loading dose (0.23 mg/kg over 30 min) followed by a continuous infusion of ARC1779 (0.06 mg/kg/h) or placebo [41] with or without desmopressin, or desmopressin alone in a randomized, double-dummy, clinical trial. After infusion of pure ARC1779 or ARC1779 combined with desmopressin, steady-state plasma concentrations of ARC1779 were 4-5 μg/ml. Infusion of ARC1779 inhibited VWF completely. Free A1 domains increased after desmopressin alone, due to VWF release. The effect of ARC1779 was reduced because of the desmopressin induced VWF. There was a 10-fold increase in the IC90 from 1.2 to 11.4 μg/ml. ARC1779 enhanced and prolonged the desmopressin induced release of VWF/FVIII and blocked the desmopressin-induced thrombocytopenia. ARC1779 decelerated the rapid clearance of VWF, particularly of the high weight multimers bound together with agglutinated platelets [41] .
ARC1779 and the possibility that it could increase VWF levels and correct thrombocytopenia in patients with VWD type IIB disease were further investigated in a subsequent trial [42] . Three thrombocytopenic patients with type 2B VWD participated in this study. These patients received a loading dose of 0.23 mg/kg ARC1779 intravenously, followed by 0.2 mg/kg/h for 72 h. With an increase of ARC1779 plasma concentrations of up to 76 μg/ml, an immediate decrease of free VWF A1 domains could be seen. VWF/FVIII levels increased within 12 h from start of infusion, with a peak being seen near the end of infusion, and then returned to baseline at follow-up. Most importantly, ARC1779 improved or even corrected thrombocytopenia in VWD type 2B patients [42] ( Table 1 ).
Aptamers pegylated with 40 kDa PEG unit
The aptamer ARC15105, another potent inhibitor of VWF, has a 40 kDa PEG [43] . Pharmacokinetics and pharmacodynamics of ARC15105 were tested in cynomolgus monkeys. Half-lives were 67 h and 65 h in monkeys after intravenous and subcutaneous injections of 20 mg/kg respectively, and subcutaneous bioavailability was 98%. ARC15105 was still shown to inhibit von Willebrand factor activity by 90% in blood samples taken after 300 h. There was no evidence of spontaneous bleeding during the whole study period, and the safety profile of ARC15105 in monkeys was favourable. The considerable increase in t 1/2 of ARC15105 (60 h) compared to ARC1779 (approx. 2-3 h) [34] is believed to be a result of the 40 kDa PEG as compared to a 20 kDa PEG for ARC1779 [43] .
Another aptamer was developed for the treatment of cardiovascular disorders. The aptamer which specifically inactivates Factor IXa and thereby decreases thrombin generation, and its antidote, were explored in murine models of stroke [44] . This duo was later named REG system. The REG1 anticoagulation system includes the pegnivacogin-RB006 (pegylated active RNA aptamer-40 kDa PEG) and anivamersen-RB007 (antidote). When pegnivacogin binds factor IXa, it blocks the activation of factor X [45] . Blocking of factor IX leads to the prolongation of the activated partial thromboplastin time (aPTT) and the degree of aPTT prolongation is directly related to the loss of factor IX activity. Inhibition of Factor IXa may possibly enhance reperfusion by its inhibition of thrombin generation. Thrombin has pleiotropic functions [46] ; it activates the inflammatory and coagulation cascades, thus it is likely responsible for ongoing microvascular thrombosis after reperfusion. The pegnivacogin significantly reduced the amount of neurological deficit associated with induction of cerebral ischemia [44] . According to the authors the decrease in thrombin levels and inflammation led to reductions in microvascular thrombosis and thus allowed for enhanced sparing of neurons, leading to improvements in neurologic function [44] . As mentioned before, this aptamer has its specific reversal agent, which can be produced by simple Watson-Crick base pairing. When the antidote is given, it only binds to the aptamer and can quickly reverse the aptamer's activity, if a level of bleeding constituting a medical emergency were to occur [47] . In contrast to unspecific antidotes such as bypassing agents, there is no risk of overshooting coagulation activity, which occasionally may lead to thrombosis or even death [48, 49] .
Following subcutaneous injection cumulative absorption of pegnivacogin was approximately 30-40% within 24 h, 50% by 36 h, 70% by 48 h, and the remaining amount was absorbed slowly over the next 3 days in a first-in-human trial. Thus, it can be seen that the absorption process here is lengthy [50] . Drugs were well tolerated and pegnivacogin provided dose-proportional anticoagulation for several days after single subcutaneous dose. The action of pegnivacogin was completely reversible when the control agent was infused [45] . In patients suffering from acute coronary syndrome, the mean plasma concentrations of pegnivacogin increased in a dose-proportional manner from 0.5 to 3.0 mg/kg. The C max of pegnivacogin was linear over the tested dose range. The overall range of t max values was 60-168 h and the median t max values were relatively consistent between doses, ranging from 84 to 90 h. The mean C max and mean t max values for 0.5 mg/kg of pegnivacogin, administered subcutaneously, were 5.2 μg/ ml and 72 h respectively. The mean residence life and the calculated mean t 1/2 were 9.6 and 6.1 days respectively, for a dose of 0.5 mg/kg [50] . The Regado 1a phase I study used aPTT measurements as a predictable pharmacodynamic response. Infusion of pegnivacogin (i.v. 1 mg/kg) extended the aPTT 3-fold and almost completely inhibited factor IX activity in patients with acute coronary syndrome [51] . The anivamersen effectively inhibited pegnivacogin and anivamersen itself was pharmacologically inert [52] . However, anivamersen can only neutralise pegnivacogin within the plasma compartment at the time of injection. Excessive amount of anivamersen, which cannot bind to pegnivacogin, will be rapidly filtered by the kidneys. Therefore, anivamersen cannot neutralise any pegnivacogin that continues to be absorbed slowly into the plasma from the subcutaneous depot. As a consequence, plasma concentrations and APTT values will begin to rise again. As pegnivacogin has a prolonged absorption phase after subcutaneous administration, the effective use of anivamersen depends upon the time of administration, as well as the duration of its infusion. For example, if the inhibition is needed during the absorption phase of pegnivacogin, continuous infusion of anivamersen will be required. Alternatively, if the reversal is needed after the complete absorption of pegnivacogin, then a single dose of anivamersen could be sufficient [45] .
ARC19499 is a pegylated aptamer (40 kDa PEG) that inhibits tissue factor pathway inhibitor (TFPI), the main regulator of the FVIIa/tissue factor pathway of coagulation [53] . Inhibition of TFPI mediates a procoagulant effect in hemophilic plasma [54] . ARC19499 was investigated in cynomolgus monkeys with induced hemophilia after FVIIIantibody administration. Bleeding times were prolonged roughly 2-fold after antibody administration (190-220%) [54] . Monkeys were treated with 300 or 600 μg/kg of ARC19499 intravenously as a single bolus. Mean aptamer levels were 6.8-8.1 μg/ml and 14.9-15.7 μg/ml, respectively. In the majority of animals, two doses of aptamer returned the bleeding time to baseline (100%). In 30% of monkeys, it took a third dose of ARC19499 to return the bleeding time to 85% [54] . Monkeys were followed for 2 h following treatment, and there was no decline in drug concentration during this observation period, so it can be concluded that the half-life must be considerably longer [54] .
Another example of a pegylated aptamer, and indeed the first aptamer on the market, is pegaptanib, a specific vascular endothelial growth factor 165 inhibitor, pegylated with two 20 kDa PEG chains [55] . Vascular endothelial growth factor (VEGF) is an important pathogenic player in age-related macular degeneration because it enhances neovascularisation and increases vascular permeability. Age-related macular degeneration (AMD) is the major cause of blindness in older individuals [56] . Whilst there are many factors causing age-related macular degeneration the main cause of vision loss is choroidal neovascularization. The timing and extent of growth and leakage of new vessels in humans are directly related to ocular vascular endothelial growth factor levels [57] . In the pathogenesis of ocular neovascularisation, the 165 isoform (VEGF165) is particularly important and is involved in all angiographic subtypes of choroidal neovascularization related to neovascular age-related macular degeneration. Pharmacokinetics in monkeys showed linear and dose-related correlations between plasma and vitreous humor pegaptanib concentrations after single bilateral doses of 0.25-2.0 mg/eye. Pegaptanib was cleared from the vitreous humor with a t 1/2 of 94 h after intra-vitreous injection [58] . The average half-lives in the vitreous humor ranged from 90 to 99 h for the different dose groups. The plasma terminal half-lives following injection into the vitreous humor were on average 89 to 102 h for the 0.5-2.0 mg/eye [58] . Comparison with the terminal t 1/2 of 9.3 h obtained by intravenous administration [59] suggests that the rate-determining step for the plasma terminal t 1/2 following injection into the vitreous humor was absorption from the eye into the plasma. A biologically active pegaptanib can be detected in the vitreous humor of monkey's eyes for at least 28 days after intravitreous injection. [58] Renal clearance was the main route of elimination for pegaptanib. No toxicological effects or antibody responses were evident [58] . In humans, pegaptanib is intra-ocularly injected (0.3 mg) every 6 weeks in patients suffering with age-related macular degeneration [60] . Such patients are typically elderly; therefore it was necessary to investigate the pharmacokinetics in patients suffering moderate renal insufficiency. A population-PK study showed that mild-to-moderate renal impairment (i.e. a decrease in clearance from 70 to 30 ml/min) doubled the area under the curve [61] . However, no dose adjustment was considered necessary for agerelated macular degeneration patients with moderate renal insufficiency [61] . A comparison between Asian and non-Asian patients showed no differences in the pharmacokinetics of pegaptanib after adjustment for other variables [61] . Intra-ocular injection of pegaptanib substantially reduced the number of patients with classic choroidal neovascularization who suffered severe vision loss (defined as loss of 15 letters) over 1 year (30% vs. 45% in the active vs. the placebo group) [62] . Pegaptanib affected neither blood pressure nor urine protein excretion.
A pegylated (40 kDa) aptamer (pegpleranib) was synthesised against platelet-derived growth factor (PDGF) and its pharmacokinetics were analysed in a rat model of mesangioproliferative glomerulonephritis model [63] . Many progressive renal diseases are caused by mesangial cell proliferation and matrix accumulation, driven by PDGF. Three and 8 days after disease induction, rats received 2.2 mg/kg PDGF-B aptamer twice-daily via intravenous infusion. The clearance from the plasma was biphasic with a t 1/2 of approximately 32 min for 47% of the compound, with 53% of the compound having a t 1/2 of 2.2 h, which was significantly shorter compared to other aptamers pegylated with 40 kDa PEG. The concentration of the aptamer in plasma after i.v. injection was 16 μg/ml at the start, after 12 h it was 0.21 μg/ml [63] . The aptamer was proven to be effective in rats.
SL1025 is an anti-IL-6 aptamer which was first synthesised without PEG unit; later-on 40 kDa PEG was added [64] . SL1026 (a pegylated version of SL1025) is a DNA aptamer with ten hydrophobic modifications (one napthylmethyl, one phenylethyl, eight benzyl and six 2′-methoxy ribose modifications) in order to enhance its nuclease stability [64] . Its pharmacokinetics was tested in a collagen-induced arthritis model in cynomolgus monkeys where SL1025 was found to delay the onset, and reduce the severity, of rheumatoid symptoms. Monkeys received a single 1, 10 or 30 mg/kg i.v. bolus dose of SL1026. Mean C max values were dose linear over the 30-fold dose range. The plasma concentration 6 h after a single infusion of a 10 mg/kg dose was only 13 ng/ml, but after repeated doses concentrations were~1000 fold greater than expected, as the clearance rate was decreasing after repeated doses. Clearance decreased from 79 to 20 ml/kg/h showing a 4-fold decrease for the highest dose compared to the lowest dose, as doses increased from 1 to 30 mg/kg [64] . The authors suggested that this is possibly due to saturation of a clearance mechanism. Terminal t 1/2 was 5.3, 164 and 51.8 h for the 1, 10 and 30 mg/kg dose groups respectively. No antibodies against the aptamer or PEG component were detected during the 34-day experimental period [64] (Table 1 ).
Comparing different PEG sizes conjugated to aptamers
Comparison of different PEG units was investigated in radio-labelled aptamers injected intraperitoneally in tumour bearing mice [65] . The authors conjugated a bi-functionalised anti-MUC1 aptamer with the 99m Technetium coordinating moiety mercapto-acetyl diglycine to either a conventional branched 20 kDa PEG or the comb-shaped 17 kDa PolyPEG. They also compared the biodistribution of modified and unmodified aptamers. Residual unpegylated aptamer was seen mainly in the small and large intestine, indicating hepatobiliary excretion after 5 h. This clearance pattern was determined by the mercapto-acetyl diglycine moiety. The pegylated aptamer with 20 kDa PEG resulted in higher levels of radioactivity than the poly-pegylated conjugate. Radioactivity after administration accumulated in the large intestine, indicating an extensive and rapid clearance through the hepatobiliary system. Pegylation reduced clearance and increased the residence times of aptamers in the body and the accumulation in bones. Consequently, the concentrations in tissues throughout the body were higher in the mice dosed with pegylated aptamers. Clearance was also influenced by the hydrodynamic volume, structure and molecular size of PEG. The highest tumour retention of pegylated aptamers occurred 5 h after injection. However, tumour uptake was significantly below that of the unpegylated aptamer. The lower tumour uptake could be caused by the decreased ability of the aptamer to penetrate the target tissue due to its increased molecular weight after conjugation to PEG. A relatively weak affinity of this aptamer for its target could possibly be the reason for a fairly modest tumour uptake of unpegylated aptamer and an even lower uptake of the pegylated aptamer. The conventional PEG conjugate showed lower tumour-to-blood ratios than the polyPEGaptamer conjugate [65] .
Another trial also compared the effect of PEG sizes. The aptamer ARC81 against transforming growth factor β2 is able to reverse the biological activity of TGFβ2 in the aqueous humor of the eyes. The anti-TGFβ2 aptamer is active in the aqueous humor and it cross-reacts with both rabbit and human TGFβ2 isoforms [66] . A pharmacokinetic study measured ARC81 and its PEG-conjugated derivatives ARC117 (20 kDa PEG) and ARC119 (40 kDa PEG) after subconjunctival injection to rabbits. Blood samples were collected at 0.5, 1, 6, 12, 24, 48, and 96 h post-dose. Aptamers were detected in the aqueous humor after subconjunctival injection. Despite the special injection site, the unconjugated aptamer entered the systemic circulation rapidly, showed rapid clearance from plasma and its maximum concentration in aqueous humor showed a delayed t max . The time delay in reaching t max of anti-TGFβ2 aptamers in plasma indicates a depot effect in the vicinity of the injection site. Pegylated derivatives showed similar plasma elimination half-lives and they achieved higher maximal concentrations compared to ARC81, t max values were delayed and clearance was generally slower, as expected [66] . Exposure and concentrations in plasma and aqueous humor in the rabbits were greater for ARC117 and ARC119 than for ARC81 (i.e. increased with size of the PEG molecules). Concentrations measured in aqueous humor were lower than corresponding plasma levels for all aptamers. Pegylated aptamers appeared in the systemic circulation much more slowly than the non-pegylated aptamer [11] . The authors concluded that these agents exhibit prolonged residence times and reach a sufficient exposure level in the subconjunctival space and aqueous compartment, which suggests that aptamer-derived therapeutic agents may be developed for the prevention of postsurgical ocular scar formation [66] .
Spiegelmers
Another possible way to improve aptamer pharmacokinetics is to introduce non-natural nucleotide analogues into the SELEX process (pre-SELEX modifications). These modified aptamers should be less susceptible to nuclease action [67] . The nucleases structure is also inherently chiral; consequently the result is stereospecific substrate recognition. As a result, in order to be accepted by these enzymes, substrate molecules have to be in correct chiral configuration. Naturally, nucleic acids (RNA and DNA) are composed of D-nucleotides; therefore Loligonucleotide should escape from enzymatic recognition and degradation. However, there is no natural developed enzymatic activity to amplify such mirror-image nucleic acids. For this reason, it is not possible to produce L-nucleic acid aptamers by employing the SELEX. Nonetheless, a method has been developed that eventually leads to the desired functional L-nucleic acid aptamers. The SELEX process is performed against an (unnatural) mirror-image target; D-aptamers recognising this (unnatural) target are attained. A natural D-aptamer against the unnatural target is selected from the libraries and logically, its structural mirror image binds with the same characteristics to the mirror image of the target. Consecutively, the corresponding mirror image configuration of said aptamer, the L-aptamer, recognises the natural target (Fig. 5) . This manufacturing process for biostable oligonucleotides was first published in 1996 [16] .
This approach teams elemental chiral principles with the screening technology of SELEX. The final result of this combination is the generation of functional mirror-image oligonucleotide ligands displaying high affinity, specificity for a given target and additionally, biological stability. The name of these ligand-binding L-oligonucleotides is 'spiegelmers' (after the German for "mirror", "Spiegel"). The first targets of functional spiegelmers were the small molecules arginine and adenosine [68] . As demonstrated for the D-adenosine specific L-RNA spiegelmer, they indeed exhibited the expected biostability. No evidence of degradation in human serum was shown, even after 60 h of incubation at 37°C [69] .
The first spiegelmer to be discussed is an improved antigonadotropin realising hormone DNA-spiegelmer (NOX 1255) which was generated with increased affinity to anti-gonadotropin realising hormone (GnRH). Animal studies followed the in vitro characterisation of NOX 1255 [70] . Furthermore, to increase the residence time of this spiegelmer in the bloodstream to N12 h, a 40 kDa PEG moiety was attached to the 5′-end of this molecule (NOX 1257). Analyses of the in vivo activity of NOX 1255 and 1257 were conducted in a rat model in order to study GnRH regulation. The efficacy parameter was luteinizing hormone concentration in the serum of castrated rats. The serum luteinizing hormone concentration returns to baseline if the GnRH activity is neutralised by an antagonist. When the elevated luteinizing hormone level had equilibrated eight days after castration, NOX 1255 was administered subcutaneously at 100 mg/kg, whilst pegylated NOX 1257 was injected intravenously at 150 mg/kg. GnRH was maximally inhibited 1.5 h after subcutaneous injection of NOX 1255 [70] . This effect decreased (rapidly) during the following hours, probably due to the fast renal clearance of the unmodified spiegelmer. The observed luteinizing hormone levels were very similar to the positive control group (which received Cetrorelix) after administration of the pegylated spiegelmer NOX 1257. Luteinizing hormone level suppression was maintained during the entire observation period of 24 h in both groups, which demonstrated the pharmacological potency of spiegelmers. However, spiegelmers, like aptamers, have to be modified in order to improve their pharmacokinetics [70] .
Emapticap pegol (NOX-E36) is a 40-nucleotide oligonucleotide spiegelmer. It acts as a binder and inhibitor of C\ \C motif-ligand 2 with high affinity and specificity [71] . The pro-inflammatory chemokine monocyte-chemotactic protein 1 (MCP-1), also called C\ \C motif-ligand 2 (CCL2), could cause insulin resistance as well as macrophage infiltration. The role of macrophages in inflammation and even in proteinuria has been underscored in diabetic mouse models [72] . Interestingly, elevated levels of urinary CCL2 were discovered in women before clinical findings of diabetic nephropathy, highlighting the potential importance of inflammatory processes in the pathophysiology of the disease [73] . One trial in mice investigated whether the late onset of therapeutic CCL2 blockade modifies the development of advanced diabetic nephropathy. The number of glomerular macrophages was reduced by 40% by subcutaneously injected emapticap (50 mg/kg three times per week). Mice were also protected from diffuse glomerulosclerosis and that significantly improved the glomerular filtration rate in unilaterally nephrectomized mice suffering from advanced glomerulopathy. When compared to control mice, emapticap reduced renal CCL2 mRNA and protein expression [71] . The authors concluded that the local expression of CCL2 in mice is reduced with blocking the CCL2-dependent renal macrophage recruitment with emapticap. Recent studies in mice have investigated whether the blockade of the CCL2 receptor CCR2 will lead to an improvement of insulin resistance and glycaemic control and indeed, it was confirmed that the blockade of CCL2 was able to improve hyperglycaemia [74] [75] [76] . Emapticap was also tested in a double-blind, randomized, multi-centre trial in diabetic patients with albuminuria [77] . Emapticap was injected at 0.5 mg/kg subcutaneously twice weekly for 12 weeks, followed by a 12 week period without treatment. In general, it was harmless and well-tolerated in diabetic nephropathy patients. After 2 weeks of treatment steady-state plasma concentrations within the therapeutic range of 355 ± 105 nM were reached. CCL2 acts as a strong chemoattractant for monocytes in humans [78] . As a result, its inhibition reduced blood monocyte counts by 15-20% within 1 week of treatment. This value remained lower than in the control group during the study period. This difference was markedly reduced four weeks after stopping treatment. Furthermore, therapy led to a reduction of the density of the CCL2 receptor CCR2 on the surface of the monocytes by 4-to 5-fold [77] . Emapticap lowered the albumin/creatinine ratio (ACR) by 29% compared to 16% in the placebo group, but did not influence blood pressure or estimated glomerular filtration rate. Even after termination of dosing, the beneficial effect of emapticap was preserved until the end of the 3-month treatment-free observation period [77] . This information suggests that CCL2 blockade may influence essential functional or structural pathophysiological mechanisms of diabetic nephropathy. This study also confirmed that blockade of CCL2 is able to improve hyperglycaemia in patients with type 2 diabetes. At Week 12, HbA1c readings decreased by −0.31% in the emapticap versus +0.05% in the placebo group [77] . The authors suggested that the common denominator for emapticap's response profile is an antiinflammatory mode of action, by reducing the amount of circulating monocytes.
Another spiegelmer is lexaptepid pegol, which blocks biological function of human hepcidin by binding to it with high affinity [79] . At the 5′-end it is covalently attached to a 40 kDa monomethoxy PEG. High circulating hepcidin concentrations are present in anaemia of chronic disease, and that results in the withdrawal of iron from the reticuloendothelial cells such as macrophages and leads to ironrestricted erythropoiesis, suppression of erythropoiesis by inflammatory cytokines, and shortened life of red blood cells [80] . As a consequence, many patients have a poor response to erythropoiesis-stimulating agents and repeated administration of i.v. iron could cause iron overload, therefore the treatment of anaemia of chronic disease is often difficult at the present time [81, 82] . A central pathophysiological process in anaemia of chronic disease can be addressed directly by targeting hepcidin. This may be both more effective and safer. Lexaptepid was examined in a randomized, placebo-controlled, double blind trial in 64 healthy subjects, after intravenous and subcutaneous single and multiple doses (4.8 mg/kg-body weight). Peak plasma concentrations after single intravenous doses of this spiegelmer were typically noted in the first hour after dosing (0.25-1 h). Mean C max increased after single intravenous doses of 0.3-4.8 mg/kg lexaptepid from 0.52 to 9.75 μmol/l respectively. As the dose of lexaptepid increased, the systemic plasma clearance was low and decreased from 293 to 115 ml/h, whilst t 1/2 increased from 14.1 to 26.1 h. Compared with the systemic plasma clearance, renal clearance was low, ranging from 5 to 7 ml/h, and the volume of distribution at steady state was approximately the plasma volume [83] . A biphasic elimination profile was seen in the lexaptepid plasma concentration-time curve, also showing a quick initial decline with a slower terminal elimination phase. In some subjects with particularly low hepcidin concentrations the slower elimination phase was absent, this might mean that the elimination of lexaptepid is slower once it binds to hepcidin. The unchanged fulllength lexaptepid was excreted via the urine and with increase of the dose of lexaptepid, throughout the first 24 h after dosing, excretion increased from 1.35 to 3.69%. The plasma concentration remained almost constant as judged by C max after first and last doses, after repeated i.v. infusion on alternate days. The pharmacokinetics did not change after repeated i.v. doses when compared to single doses. The mean C max of lexaptepid after the s.c. dose was reached after 24-51 h and was 0.090 μmol/l. Most likely due to the continued influx of drug from the s.c. depot during the elimination phase, the t 1/2 after single and repeated s.c. doses was 43 h, which was longer than that after i.v. infusion. Repeated s.c. injections of 36.5 mg on alternate days resulted in moderate accumulation in plasma with an accumulation ratio of 2.8 for C max [83] . Concerning pharmacodynamics, mean plasma concentrations of total hepcidin showed a dose-dependent increase after lexaptepid treatment, but it did not exceed the plasma concentration of lexaptepid meaning that all hepcidin was still inhibited. High single intravenous and repeated doses of lexaptepid increased serum iron, serum ferritin and transferrin saturation [83] .
The last spiegelmer to be discussed is olaptesed pegol, a pegylated RNA spiegelmer (40 kDa PEG) that inhibits the chemoattractant stromal cell-derived factor-1 (SDF-1 or CXCL12) [84] . The main role of SDF-1 is the regulation of migration or adhesion of multiple myeloma cells in the bone marrow, which is important in metastatic and bone marrow cancers. Therefore, its inhibition could be beneficial for these conditions. Maximum plasma concentrations were observed in mice at 6 and 12 h after a single s.c. injection of 10 mg/kg and the mean apparent t 1/2 was 13 h, which is comparable with the i.v. administration [85] . In a phase I clinical trial, olaptesed had a mean plasma t 1/2 of 33-40 h after i.v. infusion. It was safe and well tolerated up to the highest dose of 10.8 mg/kg. There was a reversible dose-dependent increase of the white blood cell count. The leukocyte count reached a maximum in the first 12 h, which was accompanied by a parallel rise in the numbers of CD34+ cells in the peripheral blood [84] (Table 1 ).
Safety of aptamers
Overall, aptamers are considered to be generally safe ( Table 2) . In toxicology studies, neither activation of the immune system, nor complement activation by aptamers was reported [35] . There was no evidence for off-target side effects and safety was generally very good. Aptamers are naturally non-immunogenic molecules and many analyses in preclinical and early clinical trials have failed to show aptamerinduced complement activation [52] . Infusion reactions may occur, albeit rarely, and these may be caused by complement-activation related pseudoallergic reactions [86] .
Safety of pegaptanib
The first marketed aptamer pegaptanib is described in the section above. There was no sign of antipegaptanib antibodies throughout the first year of treatment. Adverse events were mainly mild to moderate in severity, transient, and attributed to the injection and the preparation procedure itself, rather than to the study drug. Pegaptanib was also systemically well tolerated and the risk of ischemic or cardiac adverse events was low [87] . The most commonly seen ocular adverse events in the study for both the open-label cohort and the randomized cohort, were eye irritation, vitreous floaters, eye pain, punctuate keratitis, visual disturbance, and increased intraocular pressure. Mild anterior chamber inflammation was noted in eleven patients, moderate or severe Table 1 Pharmacokinetic of pegylated aptamers and spiegelmers. (i.v., intravenous; s.c., subcutaneous; ivt. Intravitreous; VWF-von Willebrand factor; TFPI-tissue factor pathway of coagulation; VEGF-vascular endothelial growth factor; PDGF-platelet-derived growth factor; IL6-interleukin 6; GnRH-gonadotropin realising hormone, CCL2-C\ \C motif-ligand 2; CXCL12(SDF1)-chemoattractant stromal cell-derived factor),~estimated from the figure or table). inflammation was not noted. The occurrence rate of endophthalmitis was 0.15% per injection. There have been occasional reports of retinal pigment epithelium tears and rare cases of anaphylactic reactions in post-approval experience with intra-vitreous pegaptanib (119). Data on drug interactions of pegaptanib are not available [60] , but oligonucleotides are not expected to interfere with the cytochrome P450 system and hence this common source of drug-drug metabolic interactions is avoided.
Name of the pegylated aptamer
Safety of ARC1779
The anti VWF aptamer ARC1779 was investigated in smaller clinical trials (see above). Overall, ARC1779 was well-tolerated in all trials. No drug-related bleedings were observed, even in patients with moderate to severe thrombocytopenia. Tolerability was excellent. In a study with healthy volunteers one subject who received the 0.3 mg/kg dose had a hypersensitivity reaction of moderate severity resulting from the intravenous push administration of undiluted ARC1779 solution [34] . This hypersensitivity reaction was associated with typical gastrointestinal and cardiovascular manifestations, with marked activation of the complement system. The reaction resolved rapidly without treatment and without sequelae. The method of administration of ARC1779 was modified by both ≥3-fold dilution of the concentration of the injected drug solution and slowing of the rate of delivery from intravenous push to a 15-minute slow intravenous bolus. After these modifications, no additional cases of hypersensitivity reactions occurred in Phase 1 studies, despite ≥3-fold dose escalation. In Phase 2 studies in TTP only one patient had a mild paraesthesia during ARC1779 infusion [39] . No adverse events related to treatment were observed in the study of ARC1779 in patients with VWD type IIB [41] .
Safety of pegnivacogin and anivamersen
There are several studies which investigated the safety of the drugantidote pair composed of pegnivacogin and anivamersen, two were conducted in healthy volunteers [50] , and one in patients with stable coronary artery disease [88, 89] . In a randomized study with an antidote controlling the modulation of factor IXa activity in patients with stable coronary artery disease, neither pegnivacogin nor anivamersen induced serious adverse events or major bleeding, and it was concluded that they were well tolerated. There were 5 cases of minor bleeding; transient cutaneous reactions in two subjects 8 and 15 min after injection [89] . Three allergic reactions were observed during the RADAR phase 2b trial in patient with acute coronary syndrome [90] . Each reaction occurred within 30 min after pegnivacogin administration and prior to the administration of contrast media [91] . After an extensive investigation it was suggested that the cause for those 3 events were elevated levels of IgG anti-PEG antibodies in those three patients [92] . Additionally, the authors reported no major bleeding events. In total, minor bleeding events, transient cutaneous reactions, gingival bleeding, one infusion site hematoma, one episode of haemorrhoidal bleeding, and the occurrence of a positive stool occult blood test were the only adverse events noted [88, 89] [52]. One serious adverse event occurred in the RADAR trial, this being an episode of transient encephalopathy, symptoms resolved rapidly with no further events. The connection between pegnivacogin and this event was not proven [52] . No dose-limiting toxicity was observed. Finally, in the phase III trial the REG1 was tested to see if it would provide greater reduction in ischaemic events compared to bivalirudin during percutaneous coronary intervention. This trial terminated early due to severe allergic reactions in patients receiving pegnivacogin and anivamersen. Severe allergic reactions were reported in ten of 1605 patients in the REG1 group compared to one severe allergic reaction reported in bivalirudin group. Regarding other endpoints, these two groups did not differ (primary efficacy endpoint, major bleeding) [93] . Recent analysis of the existing samples from the RADAR phase IIb indicated that severe allergic reactions are not caused by the aptamer itself, but that they are related to high levels of pre-existing anti-PEG antibody, the same as in the RADAR phase 2b trial [90, 92] . The levels of anti-PEG antibodies were also associated with the severity of clinical manifestations [92] .
Safety of other aptamers
Intravenous infusion of ESTA up to 500 μg of the aptamer did not result in hematologic abnormalities and did not increase the complement split products or the plasma levels of cytokines. However, after repeated injections of the mono-thioated aptamer against E-selectin, liver transaminases slightly increased with the appearance of small necrotic areas in the liver. Overall, hepatic tissue abnormalities were considered minor [18] .
The AS1411 is described above and in a phase I study there were no relevant adverse effects. In a phase II clinical study, AS1411 was safe and there were no relevant drug-related adverse events.
Safety of spiegelmers
Regarding the safety of spiegelmers it is important to note that macromolecules have an immunogenic potential and that this property is a potential safety concern in their development. Therefore, immunogenicity of spiegelmers was examined in Zimmermann rabbits. In three parallel groups, pegylated NOX 1257 and non-pegylated NOX 1255 were repeatedly administered to animals following a standard immunisation protocol. The test substances were injected alone, together with an adjuvant, or conjugated to the immunogen bovine serum albumin (BSA) plus adjuvant. There were no antibodies detected in serum from animals that had received spiegelmer with or without adjuvant. The exception was the bovine serum albumin-spiegelmer conjugates. This combination induced a minuscule immune response against the spiegelmer part; however the bovine serum albuminspecific antibody titer was very high. These results suggest that even the immunogenic potential of spiegelmers, containing non-natural oligonucleotides, is weak [94] . Emapticap pegol was also generally safe and well tolerated. No treatment-related serious adverse events occurred during the treatment and the follow-up phase [77] . Generally mild local injection site reactions were the only relevant treatmentrelated adverse events, which occurred in 18% and 4% of patients treated with emapticap or placebo, respectively [77] . Similarly, lexaptepid was also considered safe and well tolerated. There were a few transient, mostly minor adverse events, which resolved spontaneously. There were two events of a skin rash at the sites of subcutaneous lexaptepid injections both occurring 2 weeks after the last dose. The rash was treated with a topical steroid and lasted for about 2 months [83] . The authors also investigated the immunogenicity of lexaptepid and did not detect any antibodies specific to the oligonucleotide chain of lexaptepid during the whole study. However, antibodies were detected, specific to the PEG moiety in pre-dose samples with high inter-individual variability. After treatment with lexaptepid, anti-drug antibodies were detected in approximately ¼ of all subjects no matter whether they received placebo or active treatment, indicating that these were antibodies against PEG. It was suggested that those effects were not related to treatment with lexaptepid because of the lack of difference in the number of positive samples between the individual dose groups, irrespective of dose strength, dosing schedule or dosing route [83] . Finally, in trials with the olaptesed pegol, there were 26 mild and 2 moderate adverse events reported by 18 of the 48 subjects, the most frequent adverse events were headache, nasopharyngitis and rhinitis, and these were not related to the drug dose. Only four adverse events were connected to the intake of spiegelmer (headache and nausea) [84] . When given to the patient with relapsed/refractory multiple myeloma in combination with bortezomib/dexamethasone, olaptesed showed no toxicity and the drug was well tolerated [95] . 
Safety of pegylation
As mentioned before, it is possible to increase the half-life of aptamers by conjugating them to various sizes of polyethylene glycol, which decreases mainly renal clearance. As pegylation is one of the most used tools of modification, a brief description of PEG and its safety is warranted.
PEG (polyethylene glycol) has been approved by the US Food and Drug Administration for use as a medium or base in foods, cosmetics and pharmaceuticals, including topical, injectable, nasal and rectal formulations. PEG is removed from the body intact by renal (for PEGs b30 kDa) or faecal (for PEGs N20 kDa) elimination and shows little toxicity [96] . PEGs with molecular weights in the region of 20-40 kDa are routinely used to pegylate biologicals [97] . The available data show that PEG is only toxic when it is applied at high, parenteral doses. The route of excretion of the unchanged PEG is renal, explaining why the usual target organs are the kidneys [97] . The majority of toxicity data for PEGs is for low molecular weights. There was a single case of acute renal insufficiency (reversible) reported in an individual patient who received 18 l of PEG3750 (nominal average molecular weight) solution for colon cleansing, and PEG3750 is widely used for this indication [97] .
Vacuoles containing PEG in cells have been observed with pegylated biologicals and no functional deficit of the affected organ occurred. At first the vacuoles contain the pegylated biological, but in time the biological component degrades leaving only PEG in the cell. A very detailed animal study showed that these PEG vesicles can resolve with time [97] . Both single intravenous doses of 20-40 mg/kg, and repeated doses of 10 mg/kg of tumour necrosis factor (TNF) binding protein pegylated with 20 kDa PEG have been shown to cause vacuolisation in the kidneys of rats [97] . TNF binding protein conjugated to a 50 kDa PEG indicated minimal or a total absence of vacuolisation in rat kidneys. The reason for this is believed to be the reduction in the glomerular filtration of large PEG conjugates and consequently the reduction in PEG uptake by the tubular cells of the kidney [97] . PEG vacuoles were discovered in the choroid plexus ependymal cell in preclinical studies with pegylated drugs. Accumulation of PEG in vacuoles within the choroid plexus ependymal cells was only observed if the following circumstances were met: 1) the trial was performed in cynomolgus monkeys, 2) the PEG size was at least 40 kDa, 3) the study lasted for at least 6 weeks and 4) the monthly PEG exposure was a minimum of 16 mg/kg/month (120) . Because long term effects of PEG vacuoles are not known, drugs like pegylated factor IX (nonacog beta pegol) were released onto the market by the European Medicines Agency, but with an age restriction. Its indications include on-demand treatment and the prophylaxis of bleeding, including during surgical procedures, in hemophilia B patients older than ≥12 years of age (121) . Experiments have demonstrated the presence of vacuoles formed from lysosomes. Immediately after dosing TNF binding protein is present in these vacuoles, demonstrated by the immunohistochemical analysis of these vesicles. However, these vacuoles are no longer positive for TNF binding protein and are thought to still contain the PEG after a 2 month reversibility period. These vacuoles are believed to be a product of the target clearance of the pegylated conjugate and are formed in the kidney. Pegylated (20 kDa) TNF binding protein is filtered at the glomerulus and then reabsorbed in the kidney tubules, after that TNF binding protein is degraded by proteases leaving the PEG [97] . lt is Iikely that in the longterm PEG products targeted to different organs will either leave the body largely unchanged and predominantly via the kidneys, or via the liver in a similar way to PEG itself. Pegylated products and their adverse event profile is driven mostly by the specific action of the protein portion, not by the PEG [97] . Finally, it is important to mention that circulating antibodies that specifically bind PEG have been discovered, both in animals and humans, and they have been associated with reduced efficacy of and/or adverse reactions to the therapeutics modified with or containing PEG [98] . The presence of anti-PEG antibodies has been associated with anaphylactic or hypersensitivity reactions after the administration of PEG containing formulations as well as rapid clearance of various pegylated proteins in clinical trials [92, 98] . An important characteristic of anti-PEG antibody responses is that they can even be found in "treatment naive" individuals (i.e., individuals who have never undergone treatment with pegylated drugs), presumably due to prior exposure to PEG. This phenomenon is commonly referred to as "preexisting" anti-PEG antibodies [98] . Yang et al. screened a total of 377 commercially sourced plasma samples from healthy human blood donors for anti-PEG IgG and IgM levels using a competitive ELISA assay. They found that a high proportion of the plasma samples possessed detectable anti-PEG antibody levels. PEG-specific antibody levels were detected in~72% of individuals, with 18%, 25% and 30% of all samples possessing anti-PEG IgG only, anti-PEG IgM only, and both anti-PEG IgG and IgM respectively [98] . In several clinical trials adverse events or accelerated clearance of pegylated drugs have primarily been reported in subjects with high titers of anti-PEG antibodies. Several authors concluded that low or even modest levels of circulating anti-PEG antibodies in most individuals would not affect the safety and efficacy of PEG-modified therapeutics [98] . The precise threshold concentrations of anti-PEG antibodies that could begin to impact the efficacy and safety of PEG-modified therapeutics remain poorly understood, and likely varies depending on the specific therapeutic(s) in use [98] .
Conclusion
Aptamers are a new promising drug class. They have a broad spectrum of potential therapeutic applications and are relatively easy and cheap to produce. They share some characteristics with antibodies such as high affinity and specificity, but unless chemically modified they are unstable and metabolised by endogenous DNAse or RNAse enzymes and rapidly eliminated. A variety of chemical modifications to the nucleotide composition and PEG conjugation can help to overcome metabolic instability. Pegylation greatly improves the half-life of aptamer, but can lead to PEG-induced hypersensitivity reactions; otherwise aptamers are considered essentially non-immunogenic. Owing to high target specificity and lack of pharmacokinetic drug-drug interactions aptamers appear generally safe and their adverse event profile can be described as mainly target-dependent exaggerated pharmacology. Rarely infusion reactions have been seen, predominantly after rapid intravenous infusion, and this risk may be mitigated by newer generations of aptamers with improved composition and/or slower rate of administration such as subcutaneous injection.
